DDF is a pioneering venture capital fund, created to capitalize on the unique investment opportunity in dementia, a rapidly escalating public health crisis.
About the Dementia Discovery Fund
Leveraging a team of experienced investment professionals, global access to top academic centres, and industry strategic partners, the fund has cultivated unparalleled expertise in the dementia space. Since 2015, DDF-1 has nurtured a robust portfolio of 16 promising companies, over 80% of which have either attracted further investment or engaged in strategic pharma partnerships. In 2023, DDF announced its first investment out of its new fund, DDF-2.
Since its inception, DDF has grown into the leading dementia-focused VC, benefitting from extensive proprietary deal flow and the invaluable insights gained from managing >40 active dementia programs, including 13 at clinical stage. DDF aims to fill the innovation gap left by large pharmaceutical companies withdrawing from internal R&D in favour of external innovation following late clinical-stage failures.
The recent surge in scientific advancements and venture activity in the neurodegeneration field validates DDF’s positioning and its commitment to mitigating the global dementia crisis while maximizing financial returns.